CIRP is an investment vehicle and process to provide qualified investors access to U.S. (and global) markets and projects.  Please note, we seek to achieve our objectives in a socially and environmentally responsible manner.  Below are CIRP details in a nutshell.

1. If you are a qualified investor or entity limited to primarily investing and/or banking in a high risk corruption perception index region (“CPIR”) like Sub-Sahara Africa (“SSA”), then you need CIRP because your capital’s net worth needlessly shrinks daily while that of the rest of the world swells. Draconian capital market access restrictions apparently limit SSA asset mobility, which causes the lingering SSA underperforming/stranded assets dilemma.  You work harder for net worth than your non-CPIR contemporaries, but now CIRP reveals lawful US capital market access that offers bona fide US/global capital growth to qualified SSA investors. ¹ 
2. The solution to the dilemma includes Foreign Direct Investment (“FDI”) in US financial assets, such as securities (equity, debt, or derivatives), currency, and commodities. FDI is a valuable investment vehicle because:
   1. The US remains the world’s largest and strongest economy/capital market by far.
   2. The world’s “richest” countries generate wealth by funding US FDI opportunities for prime US positions. (Generally, SSA countries rank near the bottom of US FDI and, correspondingly, near the global bottom for national wealth ².)
   3. US FDI quantity is among the most accurate indicators for comparatively strong national wealth/PPP.
   4. US FDI is the single most important factor for capital growth.
3. SSA investor’s face challenges accessing US FDI/capital markets largely because:
   1. Their capital is tied to a high risk CPIR (which is a red flag for enhanced scrutiny by the US financial community);
   2. They don’t know how to navigate the gauntlet of laws, regulations and policies guarding access to US capital markets.
4. CIRP is specifically designed to address US FDI/capital markets access challenges prevalent in regions like SSA to navigate through the gauntlet.
5. CIRP addresses the US FDI/capital markets access challenges via a process, encouraged by the US Securities and Exchange Commission (“SEC”), that includes:
   1. Education. Educating the client about the US capital market access process and generic/model US capital market access solutions/strategies available for clients in regions like SSA.
   2. Facts. Determining and verifying the facts related to accreditation and capital origin.
   3. Assessment. Identifying and assessing possible risks.
   4. Law. Ensuring compliance with US laws, regulations, and policies.
   5. Accredited investor determination. Determining whether the client qualifies for accredited investor validation and if appropriate, providing that legal validation/opinion.  If the client qualifies, then:
   6. Strategy. Customize a specific US capital market access solution/strategy for the client.
   7. Execution. Help the client execute the strategy.
6. Our proprietary process/solutions includes tools such as:
   1. Data Extraction/Development. Identifying relevant historical data.
   2. Affidavits. Validating relevant facts/data.
   3. Assessment. Deploying CLFI’s Pre-Threshold US Capital Market Access Assessment tool to identify, access and address risks.
   4. Threshold Guidance White Paper. The proprietary CIRP guidance tool.
   5. Stranded Assets Steps Guidance. This tool illustrates lawful capital access.
   6. Initiating Transaction Accounts Verification/Formation. Here we verify or form any necessary corporate, trust, and/or financial accounts/entities required.
   7. Private Placement Memorandum (“PPM”)/Documents. As necessary, draft any PPM/documents in accordance with the Securities Act of 1933.
   8. Appropriate US Securities and Exchange Commission (“SEC”) certificates, forms and notices. Draft and file administrative documents as required.
   9. Private equity firm business plan (“BP”). As necessary, integrate the model private equity firm business plan into client’s strategy, or develop an entirely new BP.